Clinical Monograph • Medically Reviewed
Nexium
Esomeprazole Magnesium Delayed-Release • Proton Pump Inhibitor (PPI)
Clinical Overview: S-isomer of omeprazole providing sustained, superior 24-hour gastric acid suppression through covalent inhibition of the H+/K+ ATPase pump.
Therapeutic Indications & Pharmacodynamics
Activated in the highly acidic secretory canaliculi of gastric parietal cells, converting to its active sulphenamide form to irreversibly block the final common pathway of gastric acid production. Delivers superior mucosal healing in erosive esophagitis compared to older racemic PPIs.
Clinical Indications
Healing of erosive esophagitis, symptomatic gastroesophageal reflux disease (GERD), reduction of NSAID-associated gastric ulcer risk, H. pylori eradication regimens.
Contraindications & Precautions
Concomitant administration with rilpivirine-containing regimens, known hypersensitivity to substituted benzimidazoles.
Prescribing Profile
Available Strengths:
20mg, 40mg
20mg, 40mg
Elimination Half-Life:
1.0 to 1.5 hours (antisecretory pharmacodynamic effect persists for 24+ hours)
1.0 to 1.5 hours (antisecretory pharmacodynamic effect persists for 24+ hours)
Reviewing Physician:
Dr. Caroline Hernandez, MD
Dr. Caroline Hernandez, MD